Table. Characteristics of Included Studies.
| Source | Country (No. of Study Sites) | Recruitment | Participants | Threshold Serum CRP Level, mg/L | Threshold Predefined | Total No. | True Positive No. | False Positive No. | False Negative No. | True Negative No. | Sensitivity (95% CI) |
Specificity (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminullah et al,37 2001 | Indonesia (1) | Prospective | BW, >1 kg; GA, NR | 12 | Yes | 11 | 4 | 1 | 3 | 3 | 0.57 (0.18-0.90) | 0.75 (0.19-0.99) |
| Beltempo et al,33 2018 | Canada (1) | Retrospective | BW, NR; mean GA, 27.9 wk | 10 | Yes | 590 | 79 | 103 | 83 | 325 | 0.49 (0.41-0.57) | 0.76 (0.72-0.80) |
| Benitz et al,31 1998 | United States (3) | Prospective | BW, NR; mean GA, 32 wk | 10 | No | 184 | 33 | 41 | 20 | 90 | 0.62 (0.48-0.75) | 0.69 (0.60-0.77) |
| Bohnhorst et al,20 2012 | Germany (1) | Prospective | BW, NR; mean GA, 28 wk | 10 | Yes | 170 | 40 | 18 | 18 | 94 | 0.69 (0.55-0.80) | 0.84 (0.76-0.90) |
| Boo et al,38 | Malaysia (1) | Prospective | BW, NR; mean GA, 32 wk | 1 | Yes | 86 | 10 | 7 | 7 | 62 | 0.59 (0.33-0.82) | 0.90 (0.80-0.96) |
| Bustos and Araneda,34 2012 | Chile (1) | Prospective | BW, NR; GA, 23-35 wk | 111 | No | 53 | 3 | 1 | 22 | 27 | 0.12 (0.03-0.31) | 0.96 (0.82-1.00) |
| Chan and Ho,28 1997 | Singapore (1) | Prospective | BW, NR; mean GA, 28 wk | 10 | Yes | 152 | 14 | 26 | 16 | 96 | 0.47 (0.28-0.66) | 0.79 (0.70-0.86) |
| Choo et al,30 2012 | Korea (1) | Prospective | BW, NR; GA, >29 wk | 10 | Yes | 12 | 1 | 2 | 6 | 3 | 0.14 (0.00-0.58) | 0.60 (0.15-0.95) |
| Decembrino et al,21 2015 | Italy (1) | Prospective | BW, NR; GA, NR | 6 | No | 41 | 4 | 11 | 4 | 22 | 0.50 (0.16-0.84) | 0.67 (0.48-0.82) |
| Doellner et al,22 1998 | Norway (1) | Retrospective | BW, NR; mean GA, 38 wk | 10 | Yes | 22 | 5 | 6 | 2 | 9 | 0.71 (0.29-0.96) | 0.60 (0.32-0.84) |
| Fendler et al,23 2008 | Poland (1) | Retrospective | BW, NR; mean GA, 29 wk | 2.2 | No | 78 | 48 | 3 | 16 | 11 | 0.75 (0.63-0.85) | 0.79 (0.49-0.95) |
| Hisamuddin et al,40 2015 | Pakistan (1) | Prospective | BW, >1500 g; GA, >32 wk | 5 | Yes | 56 | 11 | 9 | 27 | 9 | 0.29 (0.15-0.46) | 0.50 (0.26-0.74) |
| Jacquot et al,24 2009 | France (1) | Prospective | BW NR; median GA, 28 wk | 10 | Yes | 73 | 17 | 6 | 13 | 37 | 0.57 (0.37-0.75) | 0.86 (0.72-0.95) |
| Kipfmueller et al,25 2015 | Germany (1) | Prospective | BW, NR; mean GA, 28 wk | 10 | Yes | 25 | 3 | 3 | 4 | 15 | 0.43 (0.10-0.82) | 0.83 (0.59-0.96) |
| Kordek et al,26 2014 | Poland (1) | Prospective | BW, NR; median GA, 30 wk | 5 | Yes | 52 | 23 | 5 | 11 | 13 | 0.68 (0.49-0.83) | 0.72 (0.47-0.90) |
| Kumar et al,39 2010 | Kenya (1) | Prospective | BW, NR; GA, NR | 5 | Yes | 142 | 55 | 60 | 1 | 26 | 0.98 (0.90-1.00) | 0.30 (0.21-0.41) |
| Ng et al,29 1997 | Hong Kong (1) | Prospective | BW, NR; mean GA 30 wk | 10 | Yes | 101 | 27 | 2 | 18 | 54 | 0.60 (0.44-0.74) | 0.96 (0.88-1.00) |
| Pynn et al,32 2015 | United States (1) | Prospective | BW, NR; median GA, 28 wk | 10 | Yes | 139 | 30 | 35 | 7 | 67 | 0.81 (0.65-0.92) | 0.66 (0.56-0.75) |
| Seibert et al,35 1990 | Australia (1) | Prospective | BW, NR, GA, 23-31 wk | 10 | Yes | 100 | 13 | 30 | 10 | 47 | 0.57 (0.34-0.77) | 0.61 (0.49-0.72) |
| Sherwin et al,36 2008 | New Zealand (1) | Prospective | BW, NR; GA, 23-42 wk | 18 | No | 52 | 14 | 1 | 20 | 17 | 0.41 (0.25-0.59) | 0.94 (0.73-1.00) |
| Utkarshni et al,41 2018 | India (1) | Prospective | BW, NR; GA, NR | 6 | Yes | 50 | 6 | 11 | 3 | 30 | 0.67 (0.30-0.93) | 0.73 (0.57-0.86) |
| Verboon-Maciolek et al,27 2006 | Netherlands (1) | Prospective | BW, NR; median GA, 29 wk | 14 | No | 66 | 24 | 14 | 13 | 15 | 0.65 (0.47-0.80) | 0.52 (0.33-0.71) |
Abbreviations: BW, birth weight; CRP, C-reactive protein; GA, gestational age; NR, not reported.
SI conversion factor: To convert CRP levels to nanomoles per liter, multiply by 9.524.